Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
9
GTBP Quote, Financials, Valuation and Earnings
Last price:
$0.63
Seasonality move
:
-1.64%
Day range:
$0.59 - $0.66
52-week range:
$0.54 - $4.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
59.35x
P/B ratio:
2.23x
Volume:
1.6M
Avg. volume:
1.1M
1-year change:
-77.01%
Market cap:
$6.7M
Revenue:
--
EPS (TTM):
-$3.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
CTOR
Citius Oncology, Inc.
|
-- | -- | -- | -- | $6.00 |
|
IDYA
IDEAYA Biosciences, Inc.
|
$60M | -$0.55 | -15.05% | -37.84% | $49.47 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $781.13 |
|
XNCR
Xencor, Inc.
|
$28.7M | -$0.70 | -43.5% | -5.69% | $28.00 |
|
ZYME
Zymeworks, Inc.
|
$29.9M | -$0.32 | -34.51% | -8.4% | $34.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
$0.63 | $8.00 | $6.7M | -- | $0.00 | 0% | 59.35x |
|
CTOR
Citius Oncology, Inc.
|
$1.11 | $6.00 | $87M | -- | $0.00 | 0% | -- |
|
IDYA
IDEAYA Biosciences, Inc.
|
$36.01 | $49.47 | $3.2B | -- | $0.00 | 0% | 14.83x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$722.80 | $781.13 | $76B | 17.30x | $0.88 | 0.49% | 5.59x |
|
XNCR
Xencor, Inc.
|
$17.31 | $28.00 | $1.2B | -- | $0.00 | 0% | 8.52x |
|
ZYME
Zymeworks, Inc.
|
$26.22 | $34.50 | $2B | -- | $0.00 | 0% | 14.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
CTOR
Citius Oncology, Inc.
|
10.5% | 12.358 | 1.22% | 0.00x |
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.755 | 1.14% | 12.20x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
XNCR
Xencor, Inc.
|
24.45% | 1.841 | 24.19% | 5.70x |
|
ZYME
Zymeworks, Inc.
|
5.58% | 0.545 | 1.46% | 6.69x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
CTOR
Citius Oncology, Inc.
|
-- | -$4.9M | -- | -- | -- | -- |
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
XNCR
Xencor, Inc.
|
$18.4M | -$47.5M | -15.54% | -20.07% | -226.29% | -$31M |
|
ZYME
Zymeworks, Inc.
|
$25M | -$22.1M | -17.82% | -18.82% | -80.07% | -$32.3M |
GT Biopharma, Inc. vs. Competitors
-
Which has Higher Returns GTBP or CTOR?
Citius Oncology, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of --. GT Biopharma, Inc.'s return on equity of -626.24% beat Citius Oncology, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M CTORCitius Oncology, Inc.-- -$0.08 $36.2M -
What do Analysts Say About GTBP or CTOR?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1170.25%. On the other hand Citius Oncology, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 440.54%. Given that GT Biopharma, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe GT Biopharma, Inc. is more attractive than Citius Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 CTORCitius Oncology, Inc.0 0 0 -
Is GTBP or CTOR More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Citius Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GTBP or CTOR?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Citius Oncology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or CTOR?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Citius Oncology, Inc. quarterly revenues of --. GT Biopharma, Inc.'s net income of -$3.1M is higher than Citius Oncology, Inc.'s net income of -$5.4M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Citius Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus -- for Citius Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M CTORCitius Oncology, Inc.-- -- -- -$5.4M
-
Which has Higher Returns GTBP or IDYA?
IDEAYA Biosciences, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of 57.38%. GT Biopharma, Inc.'s return on equity of -626.24% beat IDEAYA Biosciences, Inc.'s return on equity of -15.12%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B -
What do Analysts Say About GTBP or IDYA?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1170.25%. On the other hand IDEAYA Biosciences, Inc. has an analysts' consensus of $49.47 which suggests that it could grow by 37.38%. Given that GT Biopharma, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe GT Biopharma, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 IDYAIDEAYA Biosciences, Inc.13 2 0 -
Is GTBP or IDYA More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison IDEAYA Biosciences, Inc. has a beta of 0.040, suggesting its less volatile than the S&P 500 by 96.023%.
-
Which is a Better Dividend Stock GTBP or IDYA?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEAYA Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. IDEAYA Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or IDYA?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than IDEAYA Biosciences, Inc. quarterly revenues of $207.8M. GT Biopharma, Inc.'s net income of -$3.1M is lower than IDEAYA Biosciences, Inc.'s net income of $119.2M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while IDEAYA Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 14.83x for IDEAYA Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M
-
Which has Higher Returns GTBP or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of 38.89%. GT Biopharma, Inc.'s return on equity of -626.24% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About GTBP or REGN?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1170.25%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that GT Biopharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is GTBP or REGN More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock GTBP or REGN?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or REGN?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. GT Biopharma, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M REGNRegeneron Pharmaceuticals, Inc.5.59x 17.30x $3.8B $1.5B
-
Which has Higher Returns GTBP or XNCR?
Xencor, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -28.7%. GT Biopharma, Inc.'s return on equity of -626.24% beat Xencor, Inc.'s return on equity of -20.07%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M XNCRXencor, Inc.87.62% -$0.08 $827.7M -
What do Analysts Say About GTBP or XNCR?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1170.25%. On the other hand Xencor, Inc. has an analysts' consensus of $28.00 which suggests that it could grow by 61.76%. Given that GT Biopharma, Inc. has higher upside potential than Xencor, Inc., analysts believe GT Biopharma, Inc. is more attractive than Xencor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 XNCRXencor, Inc.9 1 0 -
Is GTBP or XNCR More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.
-
Which is a Better Dividend Stock GTBP or XNCR?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or XNCR?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Xencor, Inc.'s net income of -$6M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 8.52x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M XNCRXencor, Inc.8.52x -- $21M -$6M
-
Which has Higher Returns GTBP or ZYME?
Zymeworks, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -70.99%. GT Biopharma, Inc.'s return on equity of -626.24% beat Zymeworks, Inc.'s return on equity of -18.82%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M ZYMEZymeworks, Inc.90.64% -$0.26 $339M -
What do Analysts Say About GTBP or ZYME?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1170.25%. On the other hand Zymeworks, Inc. has an analysts' consensus of $34.50 which suggests that it could grow by 31.58%. Given that GT Biopharma, Inc. has higher upside potential than Zymeworks, Inc., analysts believe GT Biopharma, Inc. is more attractive than Zymeworks, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 ZYMEZymeworks, Inc.10 1 0 -
Is GTBP or ZYME More Risky?
GT Biopharma, Inc. has a beta of 1.524, which suggesting that the stock is 52.367% more volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.869%.
-
Which is a Better Dividend Stock GTBP or ZYME?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or ZYME?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Zymeworks, Inc. quarterly revenues of $27.6M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 14.77x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M ZYMEZymeworks, Inc.14.77x -- $27.6M -$19.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
